{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:43:02Z","timestamp":1792896182637,"version":"4.5.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T00:00:00Z","timestamp":1711324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"GUMOC Astellas Research"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Anti-osteoclast treatment with denosumab or zoledronate is known to effectively reduce the need for radiotherapy to bone and other skeletal-related events (SREs) in patients with metastatic castration-resistant prostate cancer (mCRPC). In this study, we analyze primary versus secondary initiation of bone-targeting agents (BTAs) relative to first palliative bone radiotherapy in patients dying of mCRPC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Provincial administrative databases from Ontario, Canada identified patients with prostate cancer (2007-2018, n\u2005=\u200598 646) who received continuous androgen deprivation therapy (n\u2005=\u200529 453), died of prostate cancer (2013-2018, n\u2005=\u20053864), and received life-prolonging therapy for mCRPC (n\u2005=\u20051850). Variables were collected looking back 3 years from death. Multivariable analysis explored the relationship between clinical variables and BTAs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 58% (1066\/1850) patients with mCRPC who received BTA, only 289 (25.4%) started BTA prior to first palliative bone radiotherapy as primary prevention. Eight hundred and forty-eight (74.6%) patients either never received BTA before death (n\u2005=\u2005447) or started BTA only after first bone radiotherapy (n\u2005=\u2005401). More patients received denosumab (n\u2005=\u2005825, 77%) than zoledronic acid (n\u2005=\u2005241, 23%). 51.2% (582\/1137) of palliative bone radiotherapy was initiated in the last 12 months of life. Factors associated with the use of BTA included elevated alkaline phosphatase (OR\u2005=\u20051.0, P\u2005=\u2005.023), de novo metastases (OR\u2005=\u20051.4, P\u2005=\u2005.005), medical oncologist involvement (OR\u2005=\u20052.0, P\u2005=\u2005.007), diagnosis 2012-2017 versus 2007-2011 (OR\u2005=\u20050.75, P\u2005=\u2005.034), and academic center (OR\u2005=\u20050.061, P\u2005=\u2005.007).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>A majority of patients with mCRPC never receive BTAs prior to first SRE, despite universal access and availability of these agents in Ontario. These results highlight an opportunity to improve outcomes by emphasizing early introduction of BTA in patients with mCRPC being started on systemic therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae036","type":"journal-article","created":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T17:41:24Z","timestamp":1711388484000},"page":"878-886","source":"Crossref","is-referenced-by-count":4,"title":["Real-World Evaluation of Primary Versus Secondary Prevention of Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6097-1808","authenticated-orcid":false,"given":"William J","family":"Phillips","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology, University of Ottawa , ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[{"name":"Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al , QC ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Leigh","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology, University of Ottawa , ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alborz","family":"Jooya","sequence":"additional","affiliation":[{"name":"Department of Radiology, Radiation Oncology and Medical Physics, University of Ottawa , ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Webber","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute, Clinical Epidemiology Program , ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Morgan","sequence":"additional","affiliation":[{"name":"Department of Radiology, Radiation Oncology and Medical Physics, University of Ottawa , ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"MacRae","sequence":"additional","affiliation":[{"name":"Department of Radiology, Radiation Oncology and Medical Physics, University of Ottawa , ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Bourque","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Centre Hospitalier de l\u2019Universite de Montreal , QC ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Tanuseputro","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology, University of Ottawa , ON ,","place":["Canada"]},{"name":"Ottawa Hospital Research Institute, Clinical Epidemiology Program , ON ,","place":["Canada"]},{"name":"Bruyere Research Institute , ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0347-5541","authenticated-orcid":false,"given":"Michael","family":"Ong","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology, University of Ottawa , ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,25]]},"reference":[{"key":"2024100317294612100_CIT0001","first-page":"578","article-title":"Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients","volume-title":"Hum Pathol","author":"Bubendorf","year":"2000"},{"key":"2024100317294612100_CIT0002","first-page":"465","article-title":"Management of skeletal-related events in patients with advanced prostate cancer and bone metastases: incorporating new agents into clinical practice","volume-title":"Can Urol Assoc J","author":"So","year":"2012"},{"key":"2024100317294612100_CIT0003","first-page":"e274","article-title":"A Population-based study of palliative radiation therapy for bone metastases in patients dying of prostate cancer","volume-title":"Pract Radiat Oncol","author":"Cho","year":"2019"},{"key":"2024100317294612100_CIT0004","first-page":"177","article-title":"Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999-2006","volume-title":"Prostate Cancer Prostatic Dis","author":"Sathiakumar","year":"2011"},{"key":"2024100317294612100_CIT0005","first-page":"579","article-title":"The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer","volume-title":"Ann Oncol","author":"Weinfurt","year":"2005"},{"key":"2024100317294612100_CIT0006","first-page":"6243","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume-title":"Clin Cancer Res","author":"Coleman","year":"2006"},{"key":"2024100317294612100_CIT0007","first-page":"320","article-title":"The clinical and economic impacts of skeletal-related events among medicare enrollees with prostate cancer metastatic to bone","volume-title":"Oncologist","author":"McDougall","year":"2016"},{"key":"2024100317294612100_CIT0008","first-page":"1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume-title":"J Natl Cancer Inst","author":"Saad","year":"2002"},{"key":"2024100317294612100_CIT0009","first-page":"1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume-title":"J Natl Cancer Inst","author":"Tu","year":"2002"},{"key":"2024100317294612100_CIT0010","first-page":"879","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume-title":"J Natl Cancer Inst","author":"Saad","year":"2004"},{"key":"2024100317294612100_CIT0011","first-page":"813","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume-title":"Lancet","author":"Fizazi","year":"2011"},{"key":"2024100317294612100_CIT0012","first-page":"408","article-title":"Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial","volume-title":"Lancet Oncol","author":"Smith","year":"2019"},{"key":"2024100317294612100_CIT0013","first-page":"5002","article-title":"Decreased fracture rate by mandating bone protecting agents in the EORTC 1333\/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: an updated safety analysis","volume-title":"J Clin Oncol","author":"Gillessen","year":"2021"},{"key":"2024100317294612100_CIT0014","first-page":"570","article-title":"Impact of bone-targeted therapies in chemotherapy-na\u00efve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302","volume-title":"Eur Urol","author":"Saad","year":"2015"},{"key":"2024100317294612100_CIT0015","first-page":"389","article-title":"Bone health and bone-targeted therapies for prostate cancer: American Society of Clinical Oncology Endorsement Summary of a Cancer Care Ontario Guideline","volume-title":"JCO Oncol Pract","author":"Saylor","year":"2020"},{"key":"2024100317294612100_CIT0016","first-page":"348","article-title":"Bone health and bone-targeted therapies for prostate cancer: a programme in evidence-based care \u2014 Cancer Care Ontario Clinical Practice Guideline","volume-title":"Clin Oncol","author":"Alibhai","year":"2017"},{"key":"2024100317294612100_CIT0017","first-page":"5971615","article-title":"Incidence of skeletal-related events in patients with castration-resistant prostate cancer: an observational retrospective cohort study in the US","volume-title":"Prostate Cancer","author":"Kawai"},{"key":"2024100317294612100_CIT0018","first-page":"100212","article-title":"A real-world study assessing the use of bone-targeted agents and their impact on bone metastases in patients with prostate cancer treated in clinical practice in Europe","volume-title":"J Bone Oncol","author":"Body","year":"2019"},{"key":"2024100317294612100_CIT0019","first-page":"284","article-title":"Treatment patterns and outcomes in patients with metastatic castration-resistant prostate cancer in a real-world clinical practice setting in the United States","volume-title":"Clin Genitourin Cancer","author":"George","year":"2020"},{"key":"2024100317294612100_CIT0020","first-page":"536","article-title":"An observational study of concomitant use of emerging therapies and denosumab or zoledronic acid in prostate cancer","volume-title":"Clin Ther","author":"Liede","year":"2018"},{"key":"2024100317294612100_CIT0021","first-page":"1709","article-title":"Bone targeting agents in patients with prostate cancer: general toxicities and osteonecrosis of the jaw","volume-title":"Curr Oncol","author":"Mollica","year":"2022"},{"key":"2024100317294612100_CIT0022","first-page":"2205","article-title":"Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis","volume-title":"Ann Oncol","author":"Ibrahim","year":"2015"},{"key":"2024100317294612100_CIT0023","first-page":"e77","article-title":"De-escalation of bone-targeted agents for metastatic prostate cancer","volume-title":"Curr Oncol","author":"Hong","year":"2016"},{"key":"2024100317294612100_CIT0024","first-page":"132","article-title":"A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer","volume-title":"Eur J Cancer","author":"Clemons","year":"2021"},{"key":"2024100317294612100_CIT0025","first-page":"e000652","article-title":"Bone health management in the continuum of prostate cancer disease: a review of the evidence with an expert panel opinion","volume-title":"ESMO Open","author":"Santini","year":"2020"},{"key":"2024100317294612100_CIT0026","first-page":"1348","article-title":"Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer","volume-title":"J Urol","author":"Lorente","year":"1996"},{"key":"2024100317294612100_CIT0027","first-page":"505","article-title":"Clinical features and prognostic factors for patients with bone metastases from prostate cancer","volume-title":"Asian J Androl","author":"He","year":"2012"},{"key":"2024100317294612100_CIT0028","first-page":"116243","article-title":"Initiation of bone-targeted agents in patients with bone metastases and breast or castrate-resistant prostate cancer actively treated in routine clinical practice in Europe","volume-title":"Bone","author":"von Moos","year":"2022"},{"key":"2024100317294612100_CIT0029","first-page":"3189","article-title":"Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial-FIRSTANA","volume-title":"J Clin Oncol","author":"Oudard","year":"2017"},{"key":"2024100317294612100_CIT0030","first-page":"138","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume-title":"N Engl J Med","author":"Ryan","year":"2013"},{"key":"2024100317294612100_CIT0031","first-page":"424","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume-title":"N Engl J Med","author":"Beer","year":"2014"},{"key":"2024100317294612100_CIT0032","first-page":"45","article-title":"Recent advances in the management of metastatic prostate cancer","volume-title":"JCO Oncol Pract","author":"Sayegh","year":"2022"},{"key":"2024100317294612100_CIT0033","first-page":"39","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume-title":"Lancet","author":"Smith","year":"2012"},{"key":"2024100317294612100_CIT0034","first-page":"370","article-title":"The burden of symptomatic skeletal events in castrate-resistant prostate cancer patients with bone metastases at three Canadian uro-oncology centres","volume-title":"Can Urol Assoc J","author":"Saad","year":"2018"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/10\/878\/59558386\/oyae036.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/10\/878\/59558386\/oyae036.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T17:34:37Z","timestamp":1727976877000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/29\/10\/878\/7634635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,25]]},"references-count":34,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,3,25]]},"published-print":{"date-parts":[[2024,10,3]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae036","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,3,25]]}}}